On Friday, Tegna Inc (NYSE:TGNA)’s shares declined -2.05% to $22.93.
TEGNA Media was the recipient of eight 2015 Salute to Excellence Awards from the National Association of Black Journalists (NABJ). The awards, according to NABJ, recognize “journalism that best covered the black experience or addressed issues affecting the worldwide black community” during the past year. TEGNA Media stations received eight of the 16 Salute to Excellence Awards given to local television stations, more than any other station group.
In addition, TEGNA Media’s Adrienne Broaddus, from KARE in Minneapolis, MN, was honored with the 2015 NABJ Gannett Foundation Al Neuharth Award. Her story, “A Shared Heart”, highlighted the importance of organ donation and transplantation in the African-American community.
TEGNA Inc. engages in media and digital businesses in the United States. The company operates 46 television stations that produce local programming, such as news, sports, and entertainment; and associated online sites. It also operates Cars.com that provides information about car shopping, selling, and servicing; CareerBuilder, which provides human capital solutions, such as labor market intelligence, talent administration software, and other recruitment solutions; and G/O Digital that acts as a one-stop shop for local businesses looking to connect with consumers through digital marketing. In addition, the company offers advertising and marketing solutions comprising digital and print options; and news, information, and marketing solutions in the military, defense, federal technology, and C4ISR markets.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)’s shares dropped -1.88% to $171.98.
Alexion Pharmaceuticals, Inc. (ALXN) declared financial results for the second quarter of 2015. Net product sales of Soliris® (eculizumab) grew to $636 million, a 24% enhance, contrast to $512.5 million for the same period in 2014, despite currency headwinds. Non-GAAP diluted earnings per share (EPS) for the second quarter of 2015 were $1.44, contrast to $1.12 in the second quarter of 2014. On a GAAP basis, diluted EPS for the second quarter of 2015 was $0.83 per share, influenced by $40.1 million, or $0.20 per share, related to acquisition and restructuring costs resulting from the Synageva acquisition, contrast to $0.83 in the second quarter of 2014.
Second Quarter 2015 Financial Highlights
- Net product sales of Soliris® were $636 million contrast to $512.5 million in the same quarter last year.
- Non-GAAP R&D expense was $116.6 million contrast to $85.1 million in the same quarter last year. GAAP R&D expense was $131.7 million contrast to $92.6 million in the same quarter last year.
- Non-GAAP SG&A expense was $169.1 million contrast to $139.5 million in the same quarter last year. GAAP SG&A expense was $221.4 million contrast to $159.5 million in the same quarter last year.
- Non-GAAP effective tax rate was a benefit of 0.6% contrast to tax expense of 8.0% in the same quarter last year. In Q2 2015, the Company benefitted from the utilization of operating losses from Synageva in 2015.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH and aHUS registry; Phase III clinical trials for the treatment of delayed kidney transplant graft function and myasthenia gravis; and Phase II clinical trials for the treatment of antibody mediated rejection in presensitized kidney transplant patients and neuromyelitis optica. In addition, it develops Asfotase alfa, a targeted enzyme replacement therapy that is under Phase II clinical trial for the treatment of metabolic disorders, counting hypophosphatasia; ALXN 1007, a novel humanized antibody in Phase II clinical trials for the treatment of anti-phospholipid syndrome and graft as compared to host disease; and cPMP (ALXN 1101) that is in Phase II trial for treating metabolic disorders.
At the end of Friday’s trade, Costco Wholesale Corporation (NASDAQ:COST)‘s shares dipped -1.42% to $138.48.
Costco Wholesale Corporation (NASDAQ: COST) stated net sales of $8.7 billion for the month of August, the four weeks ended August 30, 2015, a decrease of one percent from $8.8 billion during the similar period last year.
For the 16-week fourth quarter, the Company stated net sales of $35.0 billion, an enhance of one percent from $34.8 billion in the fourth quarter last year, which ended August 31, 2014.
For the 52-week fiscal year ended August 30, 2015, the Company stated net sales of $113.7 billion, an enhance of three percent from the $110.2 billion stated last year.
Additional talk about of these results is accessible in a pre-recorded telephone message. The recording can be accessed by dialing 1-855-859-2056 (conference ID 94066124). This message will be accessible through 5:00 p.m. (PT) on Friday, September 4, 2015.
The Company plans to release its operating results for the fourth quarter and fiscal year ended August 30, 2015, on September 29, 2015. A conference call to talk about these results is planned for 8:00 a.m. (PT), September 30, 2015, and will be accessible via webcast on www.costco.com (click on Investor Relations and “webcasts”).
Costco Wholesale Corporation, together with its auxiliaries, operates membership warehouses. The company offers branded and private-label products in a range of merchandise categories. It provides dry and institutionally packaged foods; snack foods, candy, tobacco, alcoholic and nonalcoholic beverages, and cleaning and institutional supplies; appliances, electronics, health and beauty aids, hardware, garden and patio, and office supplies; meat, bakery, deli, and produce; and apparel, small appliances, and home furnishings.
Rowan Companies PLC (NYSE:RDC), ended its Friday’s trading session with -0.80% loss, and closed at $17.29.
For the three months ended June 30, 2015, Rowan Companies plc (“Rowan” or the “Company”) (RDC) stated net income of $84.7 million, or $0.68 per share, contrast to $32.8 million, or $0.26 per share in the second quarter of 2014. Net income for the preceding-year quarter comprised of a non-cash asset impairment charge which reduced net income by $8.3 million, or $0.07 per share. Not taking into account the impact of this item, net income for the second quarter of 2014 was $41.1 million or $0.33 per share.
Rowan’s revenues were $508.7 million in the second quarter of 2015, an enhance of 20% over the preceding-year quarter due primarily to the contributions from the Company’s four newbuild ultra-deepwater drillships. All four drillships have commenced operations over the past year counting the Company’s fourth drillship, the Rowan Relentless, which began operating in June 2015.
Rowan Companies plc provides offshore oil and gas contract drilling services. It operates a fleet of 30 self-elevating mobile offshore jack-up drilling units, in addition to 3 ultra-deepwater drill ships. The company operates in the United States Gulf of Mexico, the United Kingdom, and Norwegian sectors of the North Sea, the Middle East, West and North Africa, Southeast Asia, and Trinidad. Rowan Companies plc was founded in 1923 and is based in Houston, Texas.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
